Novel effects of beraprost sodium on vasculatures

International Angiology

Volumn 29, Issue 2 SUPPL. 1, 2010, Pages 28-32

  Sugawara, A ^a   Kudo, M ^a   Saito, A ^a   Matsuda, K ^a   Uruno, A ^a   Ito, S ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; DNA microarray; Endothelium, vascular; Nitric oxide; Prostacyclin

Indexed keywords

BERAPROST; CAVEOLIN 1; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GELATINASE A; GHRELIN; INTERSTITIAL COLLAGENASE; KALLIKREIN 6; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC PEPTIDE RECEPTOR B; NEUROPSIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; SCATTER FACTOR; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VASCULOTROPIN C;

ANGIOGENESIS; AORTA; ARTERY OCCLUSION; ATHEROSCLEROSIS; COCULTURE; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FIBROBLAST; GENE EXPRESSION; HUMAN; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; UMBILICAL VEIN; UPREGULATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

EID: 77953547954     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62:107-33.
2. Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001;86:661-5. (Pubitemid 33086884)
3. Toyota T, Oikawa S; Beraprost Sodium Study Group. Effects of beraprost sodium (Dorner) in patients with diabetes mellitus complicated by chronic arterial obstruction. Angiology 2002;53:7-13.
4. Ohata S, Ishibashi Y, Shimada T, Takahashi N, Sugamori T, Sakane T et al. Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. Clin Exp Pharmacol Physiol 2006;33:381-7.
5. Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular celladhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 2003;52:192-8.
6. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ Res 2003;93:523-30.
7. Niwano K, Arai M, Koitabashi N, Hara S, Watanabe A, Sekiguchi K et al. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:1036-42.
8. Uruno A, Sugawara A, Kanatsuka H, Kagechika H, Saito A, Sato K et al. Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation 2005;112:727-36.
9. Uruno A, Sugawara A, Kanatsuka H, Arima S, Taniyama Y, Kudo M et al. Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogen-activated protein kinase kinase in vascular endothelial cells. Hypertens Res 2004;27:887-95.
10. Otsuka H, Akashi H, Murohara T, Okazaki T, Shintani S, Tayama K et al. The prostacyclin analog beraprost sodium augments the efficacy of therapeutic angiogenesis induced by autologous bone marrow cells. Ann Vasc Surg 2006;20:646-52.
11. Miyahara Y, Ohnishi S, Obata H, Ishino K, Sano S, Mori H et al. Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. Biochem Biophys Res Commun 2006;349:1242-9.
12. Saito A, Sugawara A, Uruno A, Kudo M, Kagechika H, Sato Y et al. All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology 2007;148:1412-23.
13. Uruno A, Sugawara A, Kudo M, Satoh F, Saito A, Ito S. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase. Hypertens Res 2008;31:2085-96.
14. Kudo M, Sugawara A, Saito A, Uruno A, Ito S. Effects of pioglitazone, belaprost, and fluvastatin on gene expression in vascular endothelial cells revealed by DNA microarray analyses. J Hypertens 2006;24(Suppl 6):238.
15. Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 2008;214:434-41.
16. Sue YM, Chung CP, Lin H, Chou Y, Jen CY, Li HF et al. PPARdelta-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells. Am J Physiol Cell Physiol 2009;297:C321-9.